Table 2.
HIV epidemic state | Variables | β | 95% CI | P | R2 |
Low level (n = 16) | HCV prevalenceb | −1.3 | −3.4 to 0.9 | 0.216 | 0.754 |
Country | 0.000 | ||||
Afghanistan | ref | ||||
Iran | −0.3 | −1.6 to 1.0 | |||
Morocco | −1.8 | −3 to −0.6 | |||
Pakistan | −0.6 | −2.4 to 1.1 | |||
Tunisia | 0.3 | −1.0 to 1.6 | |||
Study site | 0.025 | ||||
Community | ref | ||||
Prison | 1.3 | −0.3 to 3.0 | |||
Facility-based | −0.1 | −1.7 to 1.5 | |||
Mixed | 0.4 | −1.3 to 2.1 | |||
Emerging (n = 21) | HCV prevalenceb | 5.4 | 2.7–8.2 | 0.001 | 0.724 |
Country | 0.001 | ||||
Afghanistan | ref | ||||
Iran | −2.2 | −3.1 to −1.4 | |||
Morocco | −0.6 | −1.1 to −0.2 | |||
Pakistan | −1.3 | −2.2 to −0.3 | |||
Study site | 0.000 | ||||
Community | Ref | ||||
Prison | 1.0 | 0.1–2.0 | |||
Facility-based | 2.8 | 1.3–4.2 | |||
Mixed | 2.8 | 2.0–3.7 | |||
Established (n = 12) | HCV prevalenceb | 1.7 | 0.8–2.7 | 0.002 | 0.340 |
CI, confidence interval.
Weighting for sample size and using robust methods to adjust for heteroscedasticity. The displayed final models include only statistically significant covariates.
Proportion.